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Abstract: Calcified aortic valve disease is a slowly progressive disorder that ranges from mild valve thickening with no obstruction 
of blood flow, known as aortic sclerosis, to severe calcification with impaired leaflet motion or aortic stenosis. In the present work we 
describe a rapid, reproducible and effective method to carry out proteomic analysis of stenotic human valves by conventional 2-DE 
and 2D-DIGE, minimizing the interference due to high calcium concentrations. Furthermore, the protocol permits the aortic stenosis 
proteome to be analysed, advancing our knowledge in this area.
Summary: Until recently, aortic stenosis (AS) was considered a passive process secondary to calcium deposition in the aortic valves. 
However, it has recently been highlighted that the risk factors associated with the development of calcified AS in the elderly are similar 
to those of coronary artery disease. Furthermore, degenerative AS shares histological characteristics with atherosclerotic plaques, lead-
ing to the suggestion that calcified aortic valve disease is a chronic inflammatory process similar to atherosclerosis. Nevertheless, certain 
data does not fit with this theory making it necessary to further study this pathology. The aim of this study is to develop an effective 
protein extraction protocol for aortic stenosis valves such that proteomic analyses can be performed on these structures. In the present 
work we have defined a rapid, reproducible and effective method to extract proteins and that is compatible with 2-DE, 2D-DIGE and MS 
techniques. Defining the protein profile of this tissue is an important and challenging task that will help to understand the mechanisms 
of physiological/pathological processes in aortic stenosis valves.
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Introduction
Degenerative aortic valve stenosis (AS) is the most 
common of the valvular diseases and its prevalence 
increases  with  age.1,2  Calcified  aortic  valve  disease 
ranges in severity from sclerosis to stenosis, and it is 
characterised by irregular areas of increased thickening 
on the aortic side of the valve. Microscopically, these 
areas display evidence of chronic inflammation, with 
infiltration of macrophages and T-lymphocytes. There is 
also an accumulation of plasma lipoproteins, including 
LDL and Lp(a) lipoprotein, and it was recently shown 
that these lipoproteins are oxidatively modified.3,4 In 
addition, bone proteins have also been identified in 
diseased heart valves5–7 and there are several reports of 
bone formation in calcified cardiac valves.8–10
The pathogenesis of AS shares a number of fea-
tures with atherosclerosis, such as endothelial dys-
function,  increased  leukocyte  adhesion/infiltration 
and calcification11–13 and both pathologies are associ-
ated with the same clinical risk factors.14,15 However, 
despite the high prevalence and increasing morbidity 
and mortality of this condition, very little is known 
regarding the cellular and molecular factors involved 
in the development of AS and their possible relation 
with coronary artery disease.
In this sense, adopting a proteomic approach to 
study the pathogenesis of AS might provide useful 
information  to  understand  the  development  of AS 
and help define its possible relation with coronary 
atherosclerosis.
Here we present an improve protocol to extract pro-
teins from AS valves for their subsequent proteomic 
analysis. This protocol efficiently extracts most of the 
proteome of calcified valves and it is compatible with 
2-DE and 2D-DIGE, so that future clinical compara-
tive studies can be performed.
Materials and Methods
Patient selection
Heart valves with degenerative aortic stenosis (n = 20) 
were obtained from patients of both sexes (55% male, 
45% female) with an average age 75 ± 3.9, 74.16% of 
whom suffered hypertension, 33% diabetes and 52.1% 
hyperlipidemia. All patients underwent aortic valve 
replacement due to severe degenerative aortic stenosis 
or combined with ischemic miocardiopathy follow-
ing the indications established by current guidelines. 
Patients with aortic regurjitation mitral valve disease 
or suspicious of rheumatic etiology were not included. 
The protocol was approved by the ethical committee 
of “Virgen de la Salud” Hospital, Toledo.
Processing of human aortic valves: 
protein extraction
Aortic stenosis valves were processed within a max-
imum of 2 hours after surgery having maintained the 
tissue at 4 °C in RPMI medium. The valves were 
washed 3 times in PBS to reduce blood contami-
nants, and the aortic valve leaflet was then ground 
into a powder in liquid N2 with a mortar and 0.2 g 
of this powder was resuspended in 400 µl of protein 
extraction buffer (Tris 10 mM [pH 7.5], 500 mM 
NaCl,  0.1% Triton  x-100,  1%  β-mercaptoethanol, 
1 mM PMSF).16 The homogenate was centrifuged 
at 21,000 g (5840R Eppendorf) for 15 min at 4 °C 
to precipitate the membranes and tissue debris, and 
the supernatant (E1), containing most of the soluble 
proteins, was collected and stored at −20 °C. The 
pellet was then solubilized in 7 M Urea, 2 M Thio-
urea, 4% CHAPS17,18 buffer and centrifuged again 
at 21,000 g, and this second supernatant (E2) was 
separated from the pellet of tissue debris and it was 
rich  in  hydrophobic  proteins  (mainly  membrane 
proteins).
The  protein  concentration  was  determined  by  a 
Bradford-Lowry  method  (Bio-Rad  protein  assay)19 
and to check the protein composition of the extracts, 
25 µg of total protein from each sample (E1 + E2) 
was resolved by SDS-PAGE 12% (data not shown).
Two-dimensional electrophoresis (2-de)
All  the  chemicals  and  instruments  used  in  2-DE 
gels have been described previously.19,20 The protein 
extracts, E1, E2, E1 + E2 were dialysed against 2 mM 
Tris Buffer using a Mini dialysis Kit with 1kDa cut-
off (GE Healthcare). Subsequently, 300 µg of each 
protein extract was cleaned with the Clean up Kit 
(GE-Healthcare) and resuspended in rehydration buf-
fer (7M Urea, 2M Thiourea, 4% CHAPS, 1%–2% 
Ampholites and 1% TBP: Bio-Rad). Isoelectric focus-
ing (IEF) was performed in a IPGphor unit on strips 
that were actively rehydrated at 20 °C for 12 h at 
30 V to enhance protein uptake (17 cm strips; pH 
3–10 or 4–7, Bio-Rad). During focusing, the voltage Proteomic analysis of stenotic aortic valves
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was increased according to the following program: 
500 V for 30 min, 1,000 V for 1 h, 1,000–2,000 V 
in 1 h (gradient), 2,000–5,000 V in 2 h (gradient), 
5,000–8,000 V in 1 h (gradient), 8,000 V for a total 
88,000 Vhr.
Following  IEF,  the  strips  were  equilibrated  as 
described previously19,18 and the 2nd dimension SDS-
PAGE was performed according to Laemmli21 using 
a Protean II system (Bio-rad) at 25 mA/gel and 4 °C. 
The gels were then fixed overnight, stained using a 
Silver Staining kit (GE Healthcare), and they were 
then  scanned  on  GS-800  Calibrated  Densitometer 
(Bio-rad). Evaluation of the 2-DE gels was performed 
using PDQuest gel analysis software version 8.0.1 
(Bio-rad).
2d-dIge
All  chemicals  and  instruments  used  in  2D-DIGE 
were purchased from GE Healthcare. Aliquots of the 
E1, E2 and E1 + E2 samples together (50 µg) were 
separately labelled with different CyDyes (Cy5, Cy3, 
and Cy2, respectively) at a ratio of 50 µg protein to 
400 pmol CyDye. The labelled mixtures were com-
bined and loaded onto pH 4–7 17-cm Immobiline Dry 
Strips (IPG) for first dimension separation by IEF 
over 24 h. IEF was performed following the same 
program as described above and the strips were then 
loaded onto 12% polyacrylamide gels that were run 
overnight and scanned at 100 ppm using a 9400 GE 
Healthcare Typhoon scanner. Spot image analyses, 
matching and spot selection were carried out using 
DeCyder Software (GE Healthcare).
Protein identification by MALDI-TOF/TOF
All differentially expressed protein spots were manu-
ally excised and identified at the HNP Proteomic Unit. 
The proteins were automatically digested with an “Ettan 
Digester” (GE Healthcare) according to Schevchenko 
et al20 with minor modifications,21 and after digestion 
overnight at 37 °C, the peptides were extracted with 
60% acetonitrile (ACN) in 0.1% formic acid (99.5% 
purity; Sigma Aldrich). The samples were then dried 
in a speed vac and resuspended in 98% water with 
0.1% formic acid (FA) and 2% ACN. An aliquot of 
each digestion was mixed with an aliquot of the matrix 
solution (3 mg/mL α-cyano-4-Hydroxycinnamic acid, 
Sigma Aldrich) in 30% ACN, 15% 2-propanol and 
0.1% TFA, and this mixture was pipetted directly onto 
the stainless steel sample plate of the mass spectrom-
eter 384 Opti-TOF 123 × 81 mm MALDI (Applied 
Biosystems) and dried at room temperature.
The MALDI-MS/MS data were obtained in an 
automated analysis loop using a 4800 Plus MALDI 
TOF/TOF Analyzer (Applied Biosystems). Spectra 
were acquired in the reflector positive-ion mode with 
a Nd:YAG, 355 nm wavelength laser at a frequency of 
200 Hz, and between 1000 and 2000 individual spec-
tra were averaged. The experiments were acquired in 
a uniform mode with a fixed laser intensity. For the 
MS/MS 1kV analysis mode, precursors were accel-
erated to 8 kV in source 1, and they were selected at 
a relative resolution of 350 (FWHM) and metastable 
suppression. Fragment ions generated by collision 
with  air  in  a  CID  chamber  were  further  acceler-
ated at 15 kV in source 2. Mass data were analysed 
automatically with the 4000 Series Explorer Soft-
ware  version  3.5.3  (Applied  Biosystems).  Inter-
nal calibration of MALDI-TOF mass spectra was 
performed  using  two  trypsin  autolysis  ions  with 
m/z = 842.510 and m/z = 2211.105. For the calibra-
tions in the MS/MS mode, the fragment ion spec-
tra  obtained  from  Glub-fibrinopeptide  were  used 
(4700 Cal Mix, Applied Biosystems). MALDI-MS 
and MS/MS data were combined through the GPS 
Explorer  Software  Version  3.6  to  search  a  non-
redundant protein database (Swissprot 56.5) using 
the Mascot software version 2.2 (Matrix Science),22 
employing the following parameters: 50 ppm pre-
cursor tolerance; 0.6 Da MS/MS fragment tolerance; 
and allowing 1 missed cleavage, carbamidomethyl 
cysteines  and  methionine  oxidation  as  modifica-
tions. MALDI-MS(/MS) spectra and database search 
results were manually inspected in detail using the 
aforementioned software.
Results and Discussion
Understanding the nature of the biological processes 
that are associated with the disease state of a tissue 
or  organism  would  benefit  greatly  by  defining  the 
changes associated in their proteome. Defining the 
proteome of human aortic valves is an important and 
challenging task that may be fundamental to under-
stand the mechanisms and physiological/pathological 
processes that lead to the development of AS. For this gil-dones et al
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reason, here we have improved the established protocol 
for 2-DE and 2D-DIGE analysis of the human aortic 
valve proteome (see schematic flowchart in Fig. A), 
added to a sequential extraction protocol. To describe 
the complete proteome of an organ or tissue it is neces-
sary to establish an efficient extraction protocol to maxi-
mize protein solubilization. Our method was based on 
two sequential protein extractions (Fig. 1B),23,24 the 
first of which relies on a strong lysis buffer in which 
most of the soluble proteins from human valves were 
extracted (E1 extract). The second was designed to 
extract the membrane and hydrophobic proteins (E2 
extract) while finally, the pellet of cell debris was 
resuspended  in  loading  buffer.  After  SDS-PAGE 
analysis in which it was verified that it the final pellet 
basically contained salts and membrane remains (data 
not shown), this extract was discarded. This sequen-
tial protocol is very easy to carry out, it is not very 
time-consuming and it is very reproducible.
One of the major problems associated with the pro-
teomic analyses of AS valves is the high concentra-
tion of calcium that interferes with further analyses. 
For this reason the E1, E2, and E1 + E2 extracts were 
de salting using a Mini Dyalisis Kit prior to 2-DE and 
2D-DIGE. We tested different pH ranges (4–7, 3–10) 
in order to select that which was best to use in future 
studies to search for biomarkers. Thus, while more 
than 400 spots were resolved from the E1 extract in 
each gel after focusing in the pH 4–7 range, there 
were around 300 spots per gel at pH 3–10 (Fig. 2).
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Figure . diagram illustrating the protein extraction method employed for AS valve proteomic analysis. A) Flowchart representing the analysis of human 
AS valves. B) Sequential extraction protein protocol scheme.Proteomic analysis of stenotic aortic valves
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When the E2 fraction was analysed fewer spots were 
identified than in the E1 extract, although new spots 
were detected that most likely corresponded to hydro-
phobic proteins. Again, while approximately 300 spots 
were detected when the pH 4–7 IPG strip was used, 
around 200 were evident when focusing was carried out 
across the pH 3–10 range (Fig. 2). Accordingly, when 
the E1 + E2 extracts together were analysed, around 
500 spots were resolved well on the IPG strip of pH 4–7 
when compared to the 350 spots evident from the pH 
3–10 strip (Fig. 2). These data indicate that the E1 + E2 
extract permitted an important pool of proteins from AS 
valve proteome to be visualized.
DIGE technology was employed to elucidate if the 
combined E1 + E2 extract really did represent a good 
reflection of the entire AS valve proteome. With the 
E1 + E2 extract we obtained a combination of all 
the proteins solubilized by this novel two step proto-
col, simplifying the analysis in a single gel (Fig. 2). 
Spots were analysed using DeCyder software and of 
the 1178 spots in E1 and 935 in E2, 535 spots coin-
cided in both samples. Furthermore, 1346 spots were 
detected in E1 + E2 (Fig. 3). It is important to note that 
the 232 spots that did not appear in E1 + E2 extract 
corresponded with minor low intensity proteins that 
could not be identified by mass spectrometry.
Significantly, our protein extraction method was 
compatible  with  DIGE  and  the  results  obtained 
indicated  that  differential  expression  studies  can 
be carried out as the sum of both extracts (E1, E2) 
without any significant loss of information. Indeed, 
analysing the E2 extract individually could generate 
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Figure . Two dimensional gel analysis of homogenates from AS valves: A) when focused at ph 4–7 containing the soluble protein extract (e1); B) the 
extract rich in hydrophobic proteins focused at ph 4–7 (e2); c) the pooled extracts focused at ph 4–7 (e1 + e2); D) the soluble protein extract (e1) focused 
at ph 3–10; e) the hydrophobic rich protein extract focused at ph 3–10 (e2); and F) the pooled extract when focused at ph3-10 (e1 + e2).gil-dones et al
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confusing data since this sample is prefractionated. 
Furthermore, the improvement in sensitivity asso-
ciated with the 2D-DIGE technology with respect 
to conventional 2-DE was clearly evident in this 
analysis. The use of fluorescent labelling and the 
DeCyder analysis software considerably increases 
the number of protein spots that can be detected in 
the analysis when compared with more traditional 
methods. Of the protein spots detected, 100 have 
been identified and correspond to 50 different pro-
teins, and these proteins are summarized in con-
junction with their distribution on the 2DE-gels.
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